EXPAREL (Bupivacaine) Patent Expiration, LOE Window & CMS Spending
EXPAREL (Bupivacaine) by Pacira: FDA Orange Book core substance LOE 2044-07-02, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Pacira |
| FDA Application & Pathway | N022496 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2044-07-02 |
| Last Listed Patent or Exclusivity Date | 2044-07-02 |
| Orange Book Patents (*PED Extensions) | 52 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $0 |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $0 |
| Reported Wholesale Price Change (CA SB 17) | 6 WAC filings (max 21.4% 2-yr change) |